PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product TPO-RAs - Market size and forecast 2018-2023 Corticosteroids - Market size and forecast 2018-2023 IVIGs - Market size and forecast 2018-2023 Other drugs - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Special regulatory designations Increasing number of awareness programs Development of biosimilars PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Amgen Inc. CSL Ltd. Horizon Therapeutics Plc Merck & Co., Inc. Novartis AG Rigel Pharmaceuticals Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global hematology drugs market Exhibit 02: Segments of global hematology drugs market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: TPO-RAs - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Approved TPO-RAs Exhibit 21: Pipeline of TPO-RAs Exhibit 22: TPO-RAs - Year-over-year growth 2019-2023 (%) Exhibit 23: Corticosteroids - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Some of the generic sponsors for corticosteroids Exhibit 25: Corticosteroids - Year-over-year growth 2019-2023 (%) Exhibit 26: IVIGs - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Some of the available IVIGs Exhibit 28: Side effects of IVIGs Exhibit 29: Approximate Costs of IVIGs Exhibit 30: IVIGs - Year-over-year growth 2019-2023 (%) Exhibit 31: Other drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Off-label drugs for immune thrombocytopenia Exhibit 33: Other drugs - Year-over-year growth 2019-2023 (%) Exhibit 34: Market opportunity by product Exhibit 35: Customer landscape Exhibit 36: Market share by geography 2018-2023 (%) Exhibit 37: Geographic comparison Exhibit 38: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 39: North America - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in North America Exhibit 41: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 42: Europe - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in Europe Exhibit 44: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 45: Asia - Year-over-year growth 2019-2023 (%) Exhibit 46: Top 3 countries in Asia Exhibit 47: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 48: ROW - Year-over-year growth 2019-2023 (%) Exhibit 49: Top 3 countries in ROW Exhibit 50: Key leading countries Exhibit 51: Market opportunity Exhibit 52: Prevalence of associated risk factors for immune thrombocytopenia Exhibit 53: Drug development pipeline for immune thrombocytopenia Exhibit 54: Side effects associated with available drugs Exhibit 55: Alternative therapies for immune thrombocytopenia Exhibit 56: Impact of drivers and challenges Exhibit 57: Drug designations Exhibit 58: Vendor landscape Exhibit 59: Landscape disruption Exhibit 60: Vendors covered Exhibit 61: Vendor classification Exhibit 62: Market positioning of vendors Exhibit 63: Amgen Inc. - Vendor overview Exhibit 64: Amgen Inc. - Business segments Exhibit 65: Amgen Inc. - Organizational developments Exhibit 66: Amgen Inc. - Geographic focus Exhibit 67: Amgen Inc. - Key offerings Exhibit 68: Amgen Inc. - Key customers Exhibit 69: CSL Ltd. - Vendor overview Exhibit 70: CSL Ltd. - Business segments Exhibit 71: CSL Ltd. - Organizational developments Exhibit 72: CSL Ltd. - Geographic focus Exhibit 73: CSL Ltd. - Segment focus Exhibit 74: CSL Ltd. - Key offerings Exhibit 75: CSL Ltd. - Key customers Exhibit 76: Horizon Therapeutics Plc - Vendor overview Exhibit 77: Horizon Therapeutics Plc - Business segments Exhibit 78: Horizon Therapeutics Plc - Organizational developments Exhibit 79: Horizon Therapeutics Plc - Geographic focus Exhibit 80: Horizon Therapeutics Plc - Segment focus Exhibit 81: Horizon Therapeutics Plc - Key offerings Exhibit 82: Horizon Therapeutics Plc - Key customers Exhibit 83: Merck & Co. Inc. - Vendor overview Exhibit 84: Merck & Co. Inc. - Business segments Exhibit 85: Merck & Co. Inc. - Organizational developments Exhibit 86: Merck & Co. Inc. - Geographic focus Exhibit 87: Merck & Co. Inc. - Segment focus Exhibit 88: Merck & Co. Inc. - Key offerings Exhibit 89: Merck & Co. Inc. - Key customers Exhibit 90: Novartis AG - Vendor overview Exhibit 91: Novartis AG - Business segments Exhibit 92: Novartis AG - Organizational developments Exhibit 93: Novartis AG - Geographic focus Exhibit 94: Novartis AG - Segment focus Exhibit 95: Novartis AG - Key offerings Exhibit 96: Novartis AG - Key customers Exhibit 97: Rigel Pharmaceuticals Inc. - Vendor overview Exhibit 98: Rigel Pharmaceuticals Inc. - Business segments Exhibit 99: Rigel Pharmaceuticals Inc. - Organizational developments Exhibit 100: Rigel Pharmaceuticals Inc. - Key offerings Exhibit 101: Rigel Pharmaceuticals Inc. - Key customers Exhibit 102: Validation techniques employed for market sizing Exhibit 103: Definition of market positioning of vendors  

Amgen Inc. CSL Ltd. Horizon Therapeutics Plc Merck & Co., Inc. Novartis AG Rigel Pharmaceuticals Inc.